TScan Therapeutics, Inc. (TCRX) Research

TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers. The company's pipeline features programs like TSC-100 and TSC-101, which are engineered to address blood cancers by clearing remnant leukemia cells and averting disease recurrence following hematopoietic stem cell transplantation. Additionally, TScan is advancing multiple candidates, including TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, targeting solid tumor indications. Beyond its oncology efforts, the company is also engaged in vaccine development for infectious agents, such as SARS-CoV-2. TScan has formed a strategic collaboration and licensing arrangement with Novartis Institutes for BioMedical Research, Inc., aimed at pinpointing novel cancer-specific antigens derived from the T cells of particular cancer patients. Founded in 2018, TScan Therapeutics, Inc. operates from its headquarters in Waltham, Massachusetts.

Market snapshot

Symbol
TCRX
Price
$0.92
Day change
+2.23%
Market cap
$56.2M
P/E ratio
-0.96x
52-week range
0.848-2.57
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$7.50

Peer companies

  • Adicet Bio, Inc. (ACET)
  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • Fortress Biotech, Inc. (FBIO)
  • Immunic, Inc. (IMUX)
  • Lite Strategy, Inc. (LITS)
  • Nutriband Inc. (NTRB)
  • PMV Pharmaceuticals, Inc. (PMVP)
  • Relmada Therapeutics, Inc. (RLMD)

Recent insider activity

  • BAKER BROS. ADVISORS LP — A-Award (67000 shares) on 2026-05-20
  • Woods Keith — A-Award (67000 shares) on 2026-05-20
  • Nicholson Garry A — A-Award (67000 shares) on 2026-05-20
  • Gruia Gabriela — A-Award (67000 shares) on 2026-05-20
  • Dorton Katina — A-Award (67000 shares) on 2026-05-20

Open TScan Therapeutics, Inc. (TCRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.